In a recent interview actor Akshaye Khanna shared that he sleeps for 10 hours a day Is this a healthy habit or considered ...
Alkermes (NASDAQ:ALKS) used its presentation at the J.P. Morgan Healthcare Conference to outline its positioning entering ...
An announcement from Alkermes ( (ALKS) ) is now available.
Narcolepsy can lead to excessive daytime sleepiness, as well as cataplexy, a sudden loss of muscle tone. Other symptoms can include sleep paralysis and hallucinations that occur both during sleep ...
PLYMOUTH MEETING, Pa.-- (BUSINESS WIRE)--January 12, 2026-- ...
WAKIX 2025 Preliminary Net Revenue of ~$868 Million; 2026 WAKIX Net Revenue Guidance of $1.0 – $1.04 Billion on Track for Blockbuster Status in NarcolepsyOn Track to Extend the Pitolisant Franchise ...
Morning Overview on MSN
Stanford AI spots disease warnings hiding in your sleep data
While most of us treat a sleep study as a one-night inconvenience, researchers are now turning that single session into a ...
Millions of Americans suffer from sleep disorders that can lead to serious health issues, including heart disease, diabetes ...
The FDA has granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1 (NT1).
Alkermes (ALKS) shifts to fully integrated biopharma, leveraging Vibrance-2, Lybalvi growth, and Avadel buy to de-risk ...
St. Luke’s University Health Network opens a $1.8M expanded Sleep Lab at its Miners Campus, boosting access to sleep disorder ...
Alkermes wins FDA Breakthrough Therapy status for alixorexton in NT1 after Vibrance-1 data shows improvement in wakefulness.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback